Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18,379 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. Dombret H, et al. Among authors: kumar r. Blood. 2015 Jul 16;126(3):291-9. doi: 10.1182/blood-2015-01-621664. Epub 2015 May 18. Blood. 2015. PMID: 25987659 Free PMC article. Clinical Trial.
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.
Medeiros BC, McCaul K, Kambhampati S, Pollyea DA, Kumar R, Silverman LR, Kew A, Saini L, Beach CL, Vij R, Wang X, Zhong J, Gale RP. Medeiros BC, et al. Among authors: kumar r. Haematologica. 2018 Jan;103(1):101-106. doi: 10.3324/haematol.2017.172353. Epub 2017 Nov 2. Haematologica. 2018. PMID: 29097499 Free PMC article. Clinical Trial.
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H. Seymour JF, et al. Among authors: kumar r. BMC Cancer. 2017 Dec 14;17(1):852. doi: 10.1186/s12885-017-3803-6. BMC Cancer. 2017. PMID: 29241450 Free PMC article. Clinical Trial.
Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation.
Jiang G, Capo-Chichi JM, Liu A, Atenafu EG, Kumar R, Minden MD, Chang H. Jiang G, et al. Among authors: kumar r. Biol Blood Marrow Transplant. 2020 Nov;26(11):1995-2000. doi: 10.1016/j.bbmt.2020.07.017. Epub 2020 Jul 23. Biol Blood Marrow Transplant. 2020. PMID: 32712325 Free article.
Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Daher-Reyes G, Kim T, Novitzky-Basso I, Kim KH, Smith A, Stockley T, Capochichi JM, Al-Shaibani Z, Pasic I, Law A, Lam W, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, Schimmer A, McNamara C, Murphy T, Maze D, Gupta V, Sibai H, Chan S, Yee K, Minden M, Zhang Z, Schuh A, Kim DDH. Daher-Reyes G, et al. Among authors: kumar r. Bone Marrow Transplant. 2021 Aug;56(8):1908-1918. doi: 10.1038/s41409-021-01255-4. Epub 2021 Mar 25. Bone Marrow Transplant. 2021. PMID: 33767401
Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis.
Vasudevan Nampoothiri R, Tang K, Schuh A, Lam W, Maze D, Michelis FV, Chan S, Gupta V, Kim D, Kumar R, Lipton JH, Mattsson J, Minden M, Schimmer A, Sibai H, Viswabandya A, Yee K, Murphy T, Law AD. Vasudevan Nampoothiri R, et al. Among authors: kumar r. Eur J Haematol. 2023 Jun;110(6):618-625. doi: 10.1111/ejh.13940. Epub 2023 Feb 16. Eur J Haematol. 2023. PMID: 36732677
Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
Lucero J, Alhumaid M, Novitzky-Basso I, Capo-Chichi JM, Stockley T, Gupta V, Bankar A, Chan S, Schuh AC, Minden M, Mattsson J, Kumar R, Sibai H, Tierens A, Kim DDH. Lucero J, et al. Among authors: kumar r. Ann Hematol. 2024 Apr;103(4):1187-1196. doi: 10.1007/s00277-024-05639-6. Epub 2024 Jan 30. Ann Hematol. 2024. PMID: 38291275
18,379 results
You have reached the last available page of results. Please see the User Guide for more information.